Pulmonary delivery of cationic liposomal hydroxycamptothecin and 5-aminolevulinic acid for chemo-sonodynamic therapy of metastatic lung cancer
- 5 April 2021
- journal article
- research article
- Published by Elsevier BV in International Journal of Pharmaceutics
- Vol. 601, 120572
- https://doi.org/10.1016/j.ijpharm.2021.120572
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (81803453)
This publication has 42 references indexed in Scilit:
- Lung Cancer 2020Clinics in Chest Medicine, 2020
- Challenges and strategies in drug delivery systems for treatment of pulmonary infectionsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2019
- Composition design and medical application of liposomesEuropean Journal of Medicinal Chemistry, 2019
- Nanotechnologies for site specific drug delivery: Changing the narrativeInternational Journal of Pharmaceutics, 2018
- Pulmonary drug delivery system: newer patentsPharmaceutical Patent Analyst, 2017
- Liposomal andrographolide dry powder inhalers for treatment of bacterial pneumonia via anti-inflammatory pathwayInternational Journal of Pharmaceutics, 2017
- Nanotechnology approaches for inhalation treatment of lung diseasesJournal of Controlled Release, 2015
- Treating cancer with sonodynamic therapy: A reviewInternational Journal of Hyperthermia, 2015
- Cationic liposomes as carriers for aerosolized formulations of an anionic drug: Safety and efficacy studyEuropean Journal of Pharmaceutical Sciences, 2009
- Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrinJournal of Controlled Release, 2009